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Abstract--Videodensity of left heart and right heart were studied after intravenous injection f increasing dosages 
of 0.01-0.02 and 0.04 mL/kg bodyweight of Albunex ® in 10 healthy volunteers. The increase in videodensity in the 
left ventricle was always lower than in the right ventricle. Possible explanations are diffusion of gases caused by 
ambient pressures changes and change in microspheres distribution due to the sieving effect of the lung capillary 
bed. These phenomena were studied in vitro and were consistent with clinical observations. These limitations 
restrict a quantitative assessment of left heart echocontrast after intravenous injection. 
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INTRODUCTION 
Contrast echocardiography as been evolving since 
1968 when Gramiak and Shah observed a contrast 
effect following indocyanine dye injection on M- 
mode echocardiograms. Since that time, the clinical 
application of contrast echocardiography as been 
largely replaced by color Doppler flow imaging. More 
recently, contrast echocardiography gained renewed 
interest in experimental studies indicating its poten- 
tial to assess myocardial perfusion. Using intracoro- 
nary or intraaortic injections, contrast agents have 
been used to identify myocardial perfusion defects 
(Armstrong et al. 1982) and areas at risk (Kaul et al. 
1984), and to indicate coronary blood flow (Tei et al. 
1984; Ten Cate et al. 1984a) or flow reserve (Cheirifet 
al. 1988; Keller et al. 1988a). However, in order to 
accurately measure perfusion, a contrast agent must 
satisfy several criteria. It should be inert, that is, with- 
out systemic hemodynamic effects and should not 
alter coronary blood flow (Keller et al. 1988b). The 
microspheres which provide backscatter for echocar- 
diographic imaging should not be larger than red 
blood ceils, have identical velocity flow profiles and 
physiologic transit imes without impeding flow. The 
microspheres must persist long enough to perfuse the 
tissue to be imaged, and provide adequate ultrasound 
backscatter to be detected with available quipment. 
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For quantification, the ultrasound properties of the 
agent have to be known together with the concentra- 
tion and size distribution in the area of interest. 
Agents which have been used in the past have failed to 
meet one or more of these criteria. Many are hyperos- 
molar and therefore alter coronary blood flow and/or 
systemic blood pressure (Hajduczki et al. 1987; Klos- 
ter et al. 1972; Kondo et al. 1984), while others alter 
left ventricular contractility. Hand-agitated solutions 
and hydrogen peroxide contain relatively large micro- 
spheres providing ood backscatter, but impeding cap- 
illary flow and have prolonged transit imes (Feinstein 
et al. 1984; Ten Cate et al. 1984b). Also, microspheres 
used in early studies were neither small nor stable 
enough to pass through the pulmonary circulation in 
sufficient quantities to opacify the left ventricle follow- 
ing an intravenous injection (Meltzer et al. 1980). 
Experimental studies with sonicated albumin mi- 
crospheres have shown that these are sufficiently 
small and stable, with satisfactory longevity and capa- 
ble of passing through the pulmonary circulation in 
experimental animals andthat they do not alter hemo- 
dynamics, coronary blood flow, or left ventricular con- 
tractility (Keller t al. 1987). Furthermore, sonicated 
albumin microspheres can be generated in high con- 
centrations, thus providing an i tense backscatter de- 
spite their small size. Sonicated albumin therefore ap- 
pears to fulfill all the criteria set forth for an "ideal" 
myocardial contrast echo agent. 
Recently, clinical experience using intravenous A1- 
bunex ®, a sonicated albumin solution containing 
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stable microspheres of known sizes and concentra- 
tion, has been reported. The agent is safe and causes 
left heart opacification after intravenous injection 
(Feinstein et al. 1990). We studied the in vitro behav- 
ior ofAlbunex ® in order to explain the observed con- 
trast effects in the right and left ventricle after intrave- 
nous injection of increasing dosages of Albunex ® in 
humans. 
METHODS AND PATIENTS 
The studies were performed in 10 healthy male vol- 
unteers, age 20-25 years after giving written informed 
consent. All underwent a complete history and physi- 
cal examination, electrocardiogram, and laboratory 
evaluation including glucose, serum electrolytes, 
urea, creatinine, calcium, phosphate, uric acid, choles- 
terol, liver profile, complete blood count, thrombin 
time, and urinalysis. All subjects were required to be 
within 10% of their ideal body weight, with blood 
pressure between 100-140/70-90 mm Hg, heart rate 
between 50-90 beats/min, temperature less than 37.1 
centigrade, lectrocardiogram normal, and laboratory 
results without significant abnormalities. Exclusion 
criteria included previous neurologic, cardiac or lung 
disease, known right to left heart shunts, blood prod- 
uct allergies, drug or alcohol dependence, or women 
of child-bearing potential. No echocardiographic ab- 
normalities were noted. These volunteers can be de- 
fined as normal in so far as this can be established by 
complete medical examination. The protocol was ap- 
proved by the Medical Ethics Committee of the hospi- 
tal. The safety aspects have been reported recently 
(Feinstein et al. 1990). 
Two-dimensional (2D) echocardiographic examina- 
tion 
The volunteers were examined in the left lateral de- 
cubitus position using a Toshiba SSH/160A appara- 
tus with a 3.75 MHz phased array transducer. Since 
they were all healthy oung volunteers, they were able 
to breathe as superficially as possible. This was done 
to keep the 2D echo image as stable as possible during 
the injection ofAlbunex ® and to minimize the effects 
of venous return on the echocontrast images. Apical 
four-chamber views were obtained, and gain settings 
and density were optimized at the beginning of the 
examination. These settings were not changed uring 
the examination. Images were recorded on VHS vid- 
eotape. 
Albunex* administration protocol 
Subjects had a 20-gauge intravenous catheter 
placed in a large forearm vein and maintenance infu- 
sion of normal saline was initiated. The contrast agent 
used (Albunex ®, Molecular Biosystems, San Diego, 
CA, USA) is a stable, prepared albumin-based agent 
consisting of microspheres with a mean diameter be- 
tween 3-5 #m in size. Two solutions of different mi- 
crosphere concentration were administered, 4.7 x 108 
microspheres/mL (low concentration) and 8.3 x 108 
microspheres/mL (high concentration). Three differ- 
ent dosages were used: 0.01, 0.02 and 0.04 mL per kg 
body weight. Prior to the first Albunex ® injection, 
subjects received a 1 mL dose of 5% human albumin 
as control. The complete dosage regimen is given in 
Table 1. Injections were administered through a 
three-way stopcock connected to the intravenous 
catheter, and following each injection, the saline was 
allowed to run wide open for 30 s to flush the injec- 
tion. After injections, the heart rate, blood pressure, 
respiratory rate and electrocardiogram (via the single 
lead electrocardiogram displayed on the echo appara- 
tus) were recorded and a neurologic evaluation was 
made. 
Two-dimensional echo imaging was performed just 
prior to each injection and continued for 3 min follow- 
ing each injection or until contrast was no longer visi- 
ble. A final four-chamber image was recorded follow- 
ing the last injection. An example of a video recording 
just before injection and its peak density after the in- 
jection is shown in Fig. 1. 
Videodensitometry 
The video-recorded images were digitized via an 
IBM AT computer, connected to a high resolution 
frame grabber which allows acquisition of 52 frames. 
Image resolution was 512 x 512 pixels. The video 
gray-scale values were expressed in 256 (8 bit resolu- 
tion) levels, where the value 0 means black (no echo) 
and 256 white (maximum echo). The video gray-scale 
value is called density throughout the paper and is 
expressed in arbitrary units. 
For videodensity measurements, five regions of in- 
terest for each of the 52 acquired images are used. 
Position and orientation of each region can be ad- 
Table 1. Dosage regimen for the 10 volunteers 
participating in the study. Low concentrat ion = 4.7 x 10 s, 
high concentration = 8.3 x 10 s microspheres/mL. 
Injection 
no. Material Dosage Concentration 
0 Human serum albumin 1 mL 5% 
1 Albunex ~ .01 mL/kg low 
2 Albunex ® .01 mL/kg high 
3 Albunex * .02 mL/kg low 
4 Albunex ® .02 mL/kg high 
5 Albunex ® .04 mL/kg low 
6 Albunex ® .04 mL/kg high 
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Fig. 1. Representative example of a 2D-echocardiographic four-chamber view in one of the subjects. Left panel 
shows an echo image before intravenous injection of Albunex ®, right panel, 40 s after injection. Abbreviations: 
LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle. 
justed independently in all images. It is also possible 
to change the preset regions of interest in particular 
images as all information is stored on disk and is al- 
ways available for reprocessing. Measurements are 
carried out automatically once all regions are defined. 
Analysis includes measurements of the mean density 
and deviation in each region as well the correspond- 
ing time density curve. All parameters of this curve 
can be calculated, including the maximum density, 
density increase and decrease, and area under the 
curve. 
The regions of interest were placed in the right ven- 
tricular cavity (1), the inflow part of the left ventricu- 
lar cavity (2), the apex of the left ventricular cavity (3), 
the middle of the interventricular septal myocardium 
(4) and the myocardium of the lateral wall of the left 
ventricle (5) (see Fig. 2). 
When contrast was visually detected, five end-dias- 
tolic frames prior to contrast appearance were taken 
as start frame. Fifty-two successive end-diastolic 
frames were then grabbed into the computer for analy- 
sis of the time course of contrast appearance and dis- 
appearance. 
We chose end-diastolic frames because these 
images were most stable and most clearly showed the 
effects of the contrast agent. The computer stored all 
the measured intensities and constructed a time den- 
sity curve of echo contrast appearance and disappear- 
ance for the different regions. For each region the 
mean density was also determined. 
The final time-density curve was constructed by 
subtracting the baseline density and by performing a 
low-pass filtering to smooth the curve. Furthermore, 
two beats were selected for a frame-by-frame video- 
density analysis in both the left as well as the right 
ventricle in order to register cyclic variations. For the 
right ventricle, the beats were taken after sufficiently 
long time after injection when attenuation was mini- 
mal; for the left ventricle, around the time at which 
peak density occurred. 
Fig. 2. Schematic llustrations of the five regions of interest 
for determinations of the videodensities. ( 1 ) fight ventricu- 
lar cavity, (2) the inflow part of the left ventricular cavity, 
(3) the apex of the left ventricular cavity, (4) the middle of 
the interventricular septal myocardium, and (5) the myo- 
cardium of the lateral wall of the left ventricle. 
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In vitro studies 
Microscopic investigations were performed on A1- 
bunex ® (concentration fthe batch used: 3.72 micro- 
spheres/mL). Albunex ® was diluted 1:200 in 5% hu- 
man serum albumin and was put in a cavity which 
could be placed under a microscope. The human 
serum albumin was air saturated at atmospheric pres- 
sure. The pressure inside the cavity could be con- 
trolled between 0 and 200 mm Hg. A camera was 
mounted on the microscope to record the images. 
After placing the cavity with diluted Albunex ® under 
the microscope, first recordings were made under am- 
bient pressure, in order to check that the initial condi- 
tions of the human serum albumin did not influence 
the microspheres. After 1 min a static overpressure of
160 mm Hg was applied, and the microspheres' num- 
bers and shapes were visually studied. 
To calculate the influence on the backscatter power 
of Albunex ® caused by the sieving actions of the 
lungs, the size distribution of the pulmonary capillar- 
ies as described by Hogg (1987) is used. Before lung 
passage a typical size distribution of Albunex ® is as- 
sumed; after lung passage it is assumed that the larger 
microspheres have been sieved away according to the 
size distribution of the pulmonary capillaries. The 
calculated backscatter power is based on the expected 
size distribution and the theoretical model of an A1- 
bunex ® microsphere. This model theoretically de- 
scribes the attenuation and scatter properties ofa mi- 
crosphere (De Jong et al. 1992; De Jong and Hoff 
1993). 
RESULTS 
Safety 
In this study two different concentrations of AI- 
bunex ® were used. There were no laboratory, electro- 
physiologic, general physical or neurologic abnormali- 
ties detected either before, immediately after or three 
days after the study related to the injection of AI- 
bunex ® or human serum albumin (Feinstein et al. 
1990). 
Videodensitometry 
The control injection of 5% human serum albumin 
did not show an enhancement of the videodensity in
any region. The contrast effect in all patients as mea- 
sured in the left and right ventricle is shown in Fig. 3. 
In this figure the density increases for a low dose (in- 
jection 2) and for a high dose (injection 6) are given. It 
shows that the contrast effect in the right ventricle was 
always higher than in the left ventricle. Furthermore, 
Albunex ® appears in the left ventricle of all subjects at 
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Fig. 3. The measured density increase in the left and right ventricle after an intravenous injection ofAlbunex ® for 
the l0 subjects tudied. [] = Density increase in the left ventricle after intravenous injection of 0.01 mL Albunex®/ 
kg and for the high concentration fAlbunex ® (8.3* 108 microspheres/mL). [] = Density increase in the right 
ventricle after intravenous injection of 0.01 mL Albunex®/kg and for the high concentration fAlbunex ® (8.3,108 
microspheres/mL). [] = Density increase in the left ventricle after intravenous injection of 0.04 mL Albunex®/kg 
and for the high concentration of Albunex ® (8.3,108 microspheres/mL). • = Density increase in the right 
ventricle after intravenous injection of 0.04 mL Albunex®/kg and for high concentration f Albunex ® (8.3, l08 
microspheres/mL). 
Transpulmonary echocontrast • N. DE JONG et al. 283 
I/) 
¢- 
-I 
. 0  
CO 
v 
I/) 
r- 
ID 
40 
I I 
2 
2O 40 
i i 
3 
2O 40 
* i 
2O 40 
i * 
5 
20 40 
i I 
6 
20 40 
i i 
i~':'~"'"""':: 
lateral wall 
mid IVS 
LV (apex) 
LV (inno~ 
Time ( s ) 
Fig. 4. Example of measured videodensity curves of one of the subjects for the injections provided (1-6) at the 
regions of interest studied. The injection umber is denoted horizontally, the region of interest, vertically. 
the highest dose, but a positive indication is also appar- 
ent at lower dosages. For example at the lowest dos- 
ages with a high concentration fAlbunex ® (injection 
2), 8 out of 10 subjects have an increased ensity in 
the left ventricle, although nothing could be detected 
for two subjects (nos. 2, 9). The negative result in pa- 
tient no. 9 can be explained by the administration 
procedure during which a mechanical obstruction of 
the venous drainage from the left arm occurred. 
An example of contrast effects as observed in one 
patient is shown in Fig. 4. The measured time-density 
curve is displayed in each box and corresponds to45 s 
of contrast effect. The different injections are ordered 
by column while the different regions are ordered se- 
quentially by row. A variety of parameters can be cal- 
culated from these recordings, uch as time of arrival 
of contrast area under the curve, peak density, etc. 
The density curves from the midinterventricular 
septum are difficult to interpret because of "shadow- 
ing" by the contrast effect from the left ventricle apex. 
A small increase in density at the highest dosage was 
seen in the lateral wall of two subjects, one of which is 
shown in Fig. 4. 
The mean density increases together with their 
standard eviations for all objects are given in Table 
2. The different regions are shown vertically and the 
injection numbers, horizontally. There is an increase 
in density for regions 1, 2, 3 for almost all injections. 
For regions 4 and 5 there is no significant increase of 
the measured density. The average density in the right 
ventricle is higher than the left ventricle which is al- 
ready shown in Fig. 3. 
There was generally a very high attenuation caused 
by the contrast in the right ventricle and this was most 
apparent at the highest dosages. As a result, only a 
very small band along the edge of the right ventricle 
could be seen interfering with the visualization of 
more distant structures. Attenuation i  the right ven- 
tricle as high as 60 dB/cm was noticed, while in the 
left ventricle it is generally much less, 1 to 3 dB/cm. 
Table 2. Mean density increase and standard eviation for the 5 regions of interest and 6 injections. 
Injection umber 
Region 1 2 3 4 5 6 
l 29_+ 17 35-+22 46_+23 47_+ 17 47_+ 18 53_+ 15 
2 13 + 14 18 +- 18 24 +_ 18 24 +- 14 25 +- 16 33 + 16 
3 7+_ 5 16+_ 14 28_+22 25+- 16 31 +- 19 44+- 16 
4 13_+10 8 + - 8 13+ 5 12+_ 6 13_+ 7 14_+ 8 
5 5_+ 4 5_+ 3 7+_ 6 10_+13 8_+ 5 11_+ 8 
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Fig. 5. Measured videodensity ofone of the subjects represented over two entire heart cycles. The left panel shows 
the measurement in the left ventricle 20 s after injection; the right panel shows the measurement in the right 
ventricle 40 s after the same injection. 
Thedifference in density increase ranges between 3
and 45 "gray-scale" values. This suggests loss of micro- 
spheres during transit between the right and the left 
ventricles. Furthermore, there is an unexpectedly 
large variation of the increase in density. This appar- 
ent variation among normal subjects might have sev- 
eral causes including: 1) different Albunex ® charac- 
teristics, 2) different physical situation (i.e., subject 
dependency), and 3) procedure dependency. The fact 
that a smaller variability in density values is observed 
in the left ventricle suggests hat the microspheres ap- 
pearing in the left ventricle are less sensitive to these 
(a) 
Fig. 6. Microscopic view of diluted Albunex®: (a) just before overpressure, (b) i s after applying 
an overpressure of 160 mmHg, and (c) 5 s after applying an overpressure of 160 mmHg. 
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causative factor(s). This can be caused by larger micro- 
spheres, which would only appear in the right ventri- 
cle, and these larger microspheres are responsible for 
the variations seen. Since Albunex ® needs careful han- 
dling, large variations through handling of the prod- 
uct might occur. 
The measured ensity variation in the left ventricle 
and right ventricle during two heart cycles of one pa- 
tient is shown in Fig. 5. The sampling rate permitted 
12 measurements per cardiac cycle. The right ventri- 
cle density variation is about five units and is lowest at 
end-systole. This may indicate that total backscatter is 
pressure dependent. The same pattern is apparent for 
the left ventricle density measurements (range 60 
units), although the variation is much larger and con- 
sistent with the higher pressure variations in the left 
ventricle. 
In vitro results 
Albunex ® microspheres diluted 1:200 in 5% human 
serum albumin were exposed to overpressures of 160 
mm Hg. Figure 6 shows recordings of the Albunex ®
microspheres 1 and 5 s after applying an overpressure 
of 160 mm Hg. Figure 6a shows a variety of micro- 
spheres izes; all the microspheres look more or less 
spherical. Notice that the distance indicator is 10 um 
and that the bigger microspheres are overrepresented 
caused by flotation. After 1 s of overpressure, Fig. 6b 
shows that some microspheres have disappeared and 
that the shapes of all the microspheres have changed. 
This effect is caused by diffusion of the gas inside the 
microsphere to the surrounding medium. The over- 
pressure is responsible for an undersaturation f the 
gas concentration i the fluid and therefore a differ- 
ence in concentration ofgas in and outside the micro- 
spheres. Figure 6c shows an almost complete disap- 
pearance of the microspheres. The remainder of the 
microspheres are nonspherical nd have a decreased 
gas content. After approximately 20 s, all the micro- 
spheres have disappeared. 
DISCUSSION 
For a detailed report on safety and efficacy of A1- 
bunex ® after intravenous injection, we refer to the re- 
cent study (Feinstein et al. 1990) in which our center 
participated. 
This study shows that quantitative analysis of the 
contrast effect at the left side of the heart after an 
intravenous injection of Albunex ® has limitations. 
These limitations are related to the stability of the 
microspheres and the filtering action of the lung capil- 
laries. 
In the left ventricle, an attenuation of the acoustic 
power of approximately 2 to 3 dB/cm at 3.75 MHz 
due to the microspheres is noted. De Jong et al. (1992) 
have shown that this degree ofattenuation is apparent 
for Albunex ® when diluted l:10,000. In the worst 
case, the 2.5 mL injectate diluted in the blood volume 
of the human (5 L) gives a dilution of 1:2,000. There- 
fore, according to the known relationship between at- 
tenuation and concentration, it can be reasoned that 
the concentration i the left ventricle is much less 
than expected. This indicates a loss of microspheres 
between the right ventricle and left ventricle. The dif- 
ference in backscatter intensities in the left ventricle 
compared to right ventricle may be explained by three 
factors: 1) pressure dependency/diffusion of micro- 
spheres, 2) filtering action of the lungs, and 3) dilution 
effect. 
The influence of the static ambient pressure on di- 
luted Albunex ® is shown in the in vitro study. The in 
vivo situation deals with a pulsatile system. Cyclic vari- 
ation in intensities have been reported using soni- 
cared human serum albumin (Shapiro et al. 1990). 
The videodensity variation during a cardiac cycle in 
both the ventricle and especially in the left ventricle 
indicates a large pressure dependency. The effect of 
sieving action of the lungs can be demonstrated with a 
simulation of the expected backscatter density. 
When Albunex ® is intravenously injected, the lung 
capillaries will sieve the larger microspheres. Figure 7 
shows the normalized size distribution of these capil- 
laries (Hogg 1987). It shows that capillaries between 
4.5 and 5.5 um are most prevalent. The mean diame- 
ter is around 6 urn. The shaded area in the figure de- 
notes the probability for a particle with a given diame- 
ter to pass through these capillaries. For small parti- 
cles, this probability is equal to 1, for 6 #m about 0.5 
and for 10 t~m about 0.1. 
The effect on the size distribution of Albunex ® is 
shown in Fig. 8. The bar diagram gives the normal- 
ized number of counts as function of the channel di- 
ameter as measured with a Coulter Multisizer II (De 
Jong et al. 1992). The Multisizer has an aperture of 50 
tim employing 64 channels with diameters ranging 
from 1 to 35 #m. The width of each channel increases 
for larger channel diameters as indicated in the figure. 
The thick curve in the figure is calculated assuming a 
filtering given in Fig. 7 to simulate the sieving action 
of the lung. The larger microspheres disappear while 
the number of smaller microspheres remains unaf- 
fected. The consequences of this effect on backscatter- 
ing capacity can be calculated for clinically used fre- 
quencies based on a model (De Jong and Holt 1993) 
describing the acoustic properties ofAlbunex ® micro- 
Transpulmonary echocontrast • N. DE JO G eta[. 287 
Z 
1.0 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0.0 
spheres. For 2.5 MHz the model predicts a 10 dB dif- 
ference, while for 5 MHz the calculated ifference in 
backscattered power is 5 dB. 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Diameter ( pm ) 
Fig. 7. Normal ized size distr ibution of  lung capillaries (Hogg 1987) shown as bars and the probabi l i ty 
(shaded area) for a microsphere of  a part icular size to pass these capillaries. 
Albunex ® is injected undiluted intravenously. 
When the microspheres arrive in the heart, the solu- 
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Fig. 8. Normalized size distributions ofAlbunex ® as measured with the coultercounter (De Jong et al. 1992) (thin 
curve) and calculated size distribution after lung passage assuming the capillary distribution of Fig. 7 (thick curve). 
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peak concentration and an increase in contrast dura- 
tion are measured. 
The Albunex ® microspheres are filled with air. Ve- 
nous blood is not saturated for air. Furthermore, the 
gas content changes when flowing towards the heart, 
especially when passing the lung circulation. Differ- 
ences in gas concentrations between the microspheres 
and the surrounding blood will cause diffusion and 
consequently will change the microsphere itself. 
CONCLUSION 
The study shows that an intravenous injection of 
Albunex ® results in a density increase in the left ven- 
tricle in all subjects at the highest dosages used. In 
general, there is a major difference between the con- 
trast effect in the left ventricle as compared to the 
right ventricle. This is due to disappearance of micro- 
spheres, for which the lung filtration effects and the 
pressure dependency of the microspheres are consid- 
ered to be the most important. This explanation is 
supported by in vitro experiments and computations 
based on the known properties of Albunex ®. 
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